Transcriptomic risk classification for children with B cell ALL
Official title: Transcriptomic molecular risk classification for children with B cell acute lymphoblastic leukemia
Funded at Children's Hosp of Philadelphia · NIH-11350055 · Data updated 2026-11-12
This grant tests a RNA-based test to better predict relapse risk for kids with B-ALL so doctors can tailor treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Children's Hosp of Philadelphia NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $350,860 |
| NIH project number | 1UH2CA312695-01 |
| Project ID | NIH-11350055 on NIH RePORTER |
Who could benefit from this research
✓Could help
Children aged 0-11 years with B-cell acute lymphoblastic leukemia (B-ALL) undergoing risk-stratified therapy in the COG trial framework.
✕Less likely to help
Patients whose leukemia biology does not align with the identified molecular subtypes may not experience a direct benefit.
What this research studies
In this project, real-time RNA sequencing will be centralized in CLIA/CAP-certified labs to classify pediatric B-ALL patients by molecular risk. The approach aims to uncover prognostic subtypes and drivers that current tests miss, guiding risk-stratified therapy. Centralized, exome capture-based RNAseq will be integrated into next-generation COG trials to inform treatment decisions. The study emphasizes making the test clinically practical, timely, and scalable across participating labs. The effort could change how relapse risk is defined and how therapies are assigned for children with ALL.
Why it matters
Potential benefit: If successful, patients could receive more personalized therapy that reduces relapse risk while minimizing unnecessary treatment, improving outcomes and quality of life.
How similar studies have gone: Previous studies show RNAseq can reveal prognostic subtypes and drivers, supporting potential benefit of this approach.
Where this research is happening
-
Children's Hosp of Philadelphia
Philadelphia, United States Active
Researchers
- Principal investigator: Teachey, David T. — Children's Hosp of Philadelphia
- Study coordinator: Teachey, David T.
Related research
Other NIH-funded projects on the same topics.
-
Caregiver-led mobile tool to support healthy habits for kids treated for ALL
A caregiver-directed mobile program helps children who were treated for acute lymphoblastic leukemia build healthier daily routines.
-
Genomics of childhood ALL across global populations
A wide-ranging study looks at how inherited genetics influence the risk of childhood acute lymphoblastic leukemia around the world.
-
Genomics of childhood ALL across diverse populations
A large international study will look at why children everywhere get acute lymphoblastic leukemia and how genetics may influence risk.
-
Combinatorial targeting for high-risk B-cell ALL treatment
A research effort at West Virginia University is exploring a combination therapy for adult B-cell acute lymphoblastic leukemia using targeted gene silencing and a small-molecule compound to improve treatment in patients.
-
Understanding why Latino children have a higher risk of childhood ALL
This project looks at why Latino children are more likely to develop acute lymphoblastic leukemia and whether genetic ancestry plays a role, with the goal of improving prevention and outcomes.
-
Targeting obesity to improve survival for children with ALL
A new approach explores whether reducing obesity-related factors can make chemotherapy work better for kids with acute lymphoblastic leukemia.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.